Page last updated: 2024-10-27

fluorouracil and Osteogenesis Imperfecta

fluorouracil has been researched along with Osteogenesis Imperfecta in 2 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Osteogenesis Imperfecta: COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beuzeboc, P2
Pierga, JY2
Stoppa-Lyonnet, D1
Etienne, MC1
Milano, G1
Pouillart, P2
Lyonnet, DS1
Couturier, J1

Reviews

1 review available for fluorouracil and Osteogenesis Imperfecta

ArticleYear
[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
    Bulletin du cancer, 1996, Volume: 83, Issue:4

    Topics: Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B

1996

Other Studies

1 other study available for fluorouracil and Osteogenesis Imperfecta

ArticleYear
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:2

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor

1996